文献速递腹部技术与安全USCTMR

CEUS LI-RADS 对 HCC 高危人群结节诊断准确性的验证研究

Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.
PubMed 文献 · Radiol Imaging Cancer · 2020-03-27

单中心回顾性研究纳入 184 例 HCC 高危患者的 196 个结节,以病理及 CT/MR 随访为标准,评估 CEUS LI-RADS 分类的诊断效能。LR-5 诊断 HCC 的敏感度 86%、特异度 96%、阳性预测值 98%、阴性预测值 73%。结论认为 LR-5 特异度优秀,可自信诊断 HCC 而无需病理证实。

要点

  • LR-5 诊断 HCC 特异度 96%、阳性预测值 98%,支持无病理确诊。
  • 消退时间大于 60 秒是预测 HCC 的最强 CEUS 特征。
  • 消退时间小于 60 秒是非肝细胞恶性肿瘤的最强预测特征。

关键影像表现/征象

  • LR-5 分类诊断 HCC 的敏感度 86%(119/139)、特异度 96%(55/57)、阳性预测值 98%(119/121)、阴性预测值 73%(55/75)。
  • LR-5 的 2 例假阳性分别为胆管癌和混合型肝细胞-胆管癌。
  • 样本中其余 8 例胆管癌均被正确归为 LR-M。
  • 多变量 logistic 回归显示消退时间大于 60 秒是预测 HCC 诊断的最强 CEUS 特征,消退时间小于 60 秒是非肝细胞恶性肿瘤的最强预测特征。
  • 归为 LR-M 和 LR-4 的 HCC 结节比例分别为 35% 和 20%。

诊断标准与关键数值

  • LR-5 分类诊断 HCC:敏感度 86%(119/139)、特异度 96%(55/57)、阳性预测值 98%(119/121)、阴性预测值 73%(55/75)。
  • 消退时间大于 60 秒为预测 HCC 的最强 CEUS 特征;消退时间小于 60 秒为非肝细胞恶性肿瘤的最强预测特征。
  • 阅片者间 LI-RADS 分类的 Light κ 一致性为 90%。

临床应用与阅片要点

  • 日常阅片可按 CEUS LI-RADS 对高危患者结节分类,LR-5 可支持 HCC 的影像诊断。
  • 注意消退时间:大于 60 秒倾向 HCC,小于 60 秒需警惕非 HCC 恶性肿瘤(如胆管癌)。
  • LR-5 存在假阳性可能,需结合临床与其它影像综合判断。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To validate the contrast agent-enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) algorithm for accurate diagnosis of hepatocellular carcinoma (HCC) and categorization of all nodules encountered in patients at risk for HCC.

MATERIALS AND METHODS: A single-center retrospective review of 196 nodules in 184 patients at risk for HCC (consisting of 139 HCCs, 18 non-HCC malignancies, and 39 benign nodules) was performed in a three-reader blinded read format, with the use of the CEUS LI-RADS algorithm. Pathologic confirmation was available for 143 nodules (122 HCCs, 18 non-HCC malignancies, and three benign nodules). Nodule sizes ranged between 1.0 and 16.2 cm. Nodules assessed with contrast-enhanced US were assigned various CEUS LI-RADS categories by three blinded readers. CEUS LI-RADS categorization was then compared against histopathologic findings, concurrent CT, and/or MR images or follow-up imaging to assess diagnostic accuracy of CEUS LI-RADS. In addition, the proportion of HCC in all LI-RADS (LR) categories, univariable and multivariable feature analysis, and interrater agreement using Light κ were determined.

RESULTS: The LR-5 category, determined through radiologist categorization of nodules using the CEUS LI-RADS criteria, showed sensitivity, specificity, positive predictive value, and negative predictive value of 86% (119 of 139), 96% (55 of 57), 98% (119 of 121), and 73% (55 of 75), respectively, for the diagnosis of HCC. Two false-positive cases of LR-5 included a cholangiocarcinoma and a combined hepatocellular and cholangiocarcinoma. The remainder of the cholangiocarcinomas in the sample (n = 8) were appropriately categorized as LR-M. Multivariable logistic regression analysis showed that washout of greater than 60 seconds was the contrast-enhanced US feature most predictive of HCC diagnosis, whereas washout of less than 60 seconds was the feature most predictive of nonhepatocellular malignancy. The proportion of HCC nodules categorized in the LR-M and LR-4 categories was 35% and 20%, respectively. Light κ agreement between readers for LI-RADS categorization was 90%.

CONCLUSION: This study showed excellent specificity for the CEUS LI-RADS LR-5 category, allowing for confident imaging diagnosis of HCC, without necessity for pathologic confirmation. In addition, there was accurate differentiation of HCC from non-HCC malignancies and benign nodules. Only a single cholangiocarcinoma was misdiagnosed as category LR-5, with the remainder of the cholangiocarcinomas in the sample appropriately characterized as category LR-M.Keywords: Abdomen/GI, Evidence Based Medicine, Liver, Neoplasms-Primary, Ultrasound-Contrast© RSNA, 2020.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Makoyeva A, Kim TK, Jang HJ, et al. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study. Radiol Imaging Cancer. 2020. PMID: 33778701. doi:10.1148/rycan.2020190014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。